- Clinical Trials
- April 2025
- 60 Pages
Global
From €1118EUR$1,250USD£968GBP
- Report
- March 2026
- 506 Pages
Global
From €5233EUR$5,850USD£4,530GBP
- Report
- February 2026
- 250 Pages
Global
From €4016EUR$4,490USD£3,477GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1789EUR$2,000USD£1,549GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1118EUR$1,250USD£968GBP
- Report
- May 2024
- 134 Pages
Global
From €3577EUR$3,999USD£3,097GBP
- Report
- December 2022
- 42 Pages
Global
From €3131EUR$3,500USD£2,711GBP
- Report
- October 2022
- 69 Pages
Global
From €3131EUR$3,500USD£2,711GBP
- Report
- October 2022
- 41 Pages
Global
From €3131EUR$3,500USD£2,711GBP
- Report
- August 2024
- 78 Pages
Global
From €3500EUR$4,191USD£3,136GBP
- Report
- November 2021
- 844 Pages
Global
From €4473EUR$5,000USD£3,872GBP
The Metabotropic Glutamate Receptor (mGluR) market is a subset of the Central Nervous System (CNS) drugs market. mGluRs are a class of G-protein coupled receptors that are involved in a variety of physiological processes, including learning and memory, pain perception, and anxiety. mGluRs are also implicated in a number of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and schizophrenia. As such, mGluR-targeted drugs are being developed to treat these conditions.
The mGluR market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms developing mGluR-targeted drugs. Companies such as Merck, Pfizer, Novartis, and Eli Lilly are actively researching and developing mGluR-targeted drugs. Additionally, a number of smaller biotechnology firms, such as Neurocrine Biosciences, ACADIA Pharmaceuticals, and Ovid Therapeutics, are also developing mGluR-targeted drugs. Show Less Read more
